Trevena, Inc. (TRVN)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Trevena, Inc. (TRVN)
Company Performance

Current Price

as of Oct 16, 2024

$2.34

P/E Ratio

N/A

Market Cap

$2M

Description

Trevena, Inc. is a biopharmaceutical company, which focuses on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.

Metrics

Overview

  • HQChesterbrook, PA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerTRVN
  • Price$2.34+9.86%

Trading Information

  • Market Cap$2.00M
  • Float93.29%
  • Average Daily Volume (1m)48,265
  • Average Daily Volume (3m)119,529
  • EPS-$55.32

Company

  • Revenue$0.44M
  • Rev Growth (1yr)-89.24%
  • Net Income-$4.89M
  • Gross Margin40.92%
  • EBITDA Margin-1,973.54%
  • EBITDA-$6.41M
  • EV$24.75M
  • EV/Revenue55.75
  • P/EN/A
  • P/S4.49
  • P/BN/A
Documents
SEC Filings
8-K (2024-10-10)
8-K (2024-10-04)
8-K (2024-08-30)
8-K (2024-08-08)
8-K (2024-07-08)
8-K (2024-06-18)
8-K (2024-05-15)
8-K (2024-04-22)
8-K (2024-04-09)
8-K (2024-04-01)
8-K (2024-03-21)
8-K (2024-03-06)
8-K (2024-02-01)
8-K (2024-01-08)
8-K (2023-12-28)
8-K (2023-11-14)
8-K (2023-11-09)
8-K (2023-10-02)
8-K (2023-09-18)
8-K (2023-09-06)
8-K (2023-09-01)
8-K (2023-08-14)
8-K (2023-07-20)
8-K (2023-06-26)
8-K (2023-06-20)
8-K (2023-05-30)
8-K (2023-05-15)
8-K (2023-05-09)
8-K (2023-05-08)
8-K (2023-04-21)
8-K (2023-03-30)
8-K (2023-03-13)
8-K (2023-01-09)
10-Q (2024-08-08)
10-Q (2024-05-15)
10-Q (2023-11-14)
10-Q (2023-08-14)
10-Q (2023-05-15)
10-K (2024-04-01)
10-K (2023-03-30)
Earnings Calls
Earnings Report 2023Q3
Earnings Report (2023-11-14)
Earnings Report (2023-05-15)
Factset
Factset Business Description
Factset Street Account
Trevena reports Q3 EPS ($0.57) vs year-ago ($2.24) ($0.60, 0.00) (2023-11-14T12:02:33Z)
Trevena Chariman Leon Moulder resigns effective immediately; Carrie Bourdow appointed as Chair of the board - 8-K ($0.59, 0.00) (2023-11-09T22:57:04Z)
Trevena announces completion of initial analysis of OLINVYK continuous respiratory monitoring data from VOLITION study ($0.60, 0.00) (2023-10-02T11:05:51Z)
Trevena announces acceptance of abstract examining the use of OLINVYK in patients with acute burn injuries ($0.58, 0.00) (2023-11-30T12:01:44Z)